je.st
news
Tag: proportion
Mitsubishi Motors to raise proportion of electrified vehicles in total sales to 50% by 2030
2020-11-05 13:55:38| Green Car Congress
Study finds significant proportion of childhood asthma cases may be attributable to air pollution
2019-08-08 12:55:37| Green Car Congress
Tags: to
air
study
significant
Proportion of mums in work 'up 50% since mid-1970s'
2018-04-27 09:45:09| BBC News | Business | UK Edition
But the increases have been largest among the partners of higher-earning men, says the IFS.
Tags: work
since
proportion
mums
Germany increases proportion of power from renewable sources to 35%
2017-07-03 01:00:00| Power Technology
Germany has increased the proportion of its electricity produced by renewable energy to 35% in the first six months of 2017, up from 33% in 2016, according to the BEE renewable energy association.
Tags: to
power
germany
sources
FDA Approves Mercks KEYTRUDA (pembrolizumab) in Metastatic NSCLC for First-Line Treatment of Patients Whose Tumors Have High PD-L1 Expression (Tumor Proportion Score [TPS] of 50 Percent or More) With No EGFR or ALK Genomic Tumor Aberrations
2016-10-25 00:04:00| Merck.com - Product News
Dateline City: KENILWORTH, N.J. KEYTRUDA is the Only Anti-PD-1 Therapy Approved in First-Line Treatment of Metastatic NSCLC; KEYTRUDA Demonstrated Superior Progression-Free and Overall Survival Compared to Chemotherapy in Patients Whose Tumors Expressed High Levels of PD-L1 FDA Also Approves a Labeling Update for KEYTRUDA for the Treatment of Patients with Metastatic NSCLC Whose Tumors Express PD-L1 (TPS of One Percent or More) With Disease Progression On or After Platinum-Containing Chemotherapy; Patients With EGFR or ALK Genomic Tumor Aberrations Should Have Disease Progression On FDA-Approved Therapy for These Aberrations Prior to Receiving KEYTRUDA KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA (pembrolizumab), the companys anti-PD-1 (programmed death receptor-1) therapy, for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have high PD-L1 expression (tumor proportion score [TPS] of 50 percent or more) as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations. Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558Courtney Ronaldo, 908-236-1108orInvestors:Teri Loxam, 908-740-1986Amy Klug, 908-740-1898 Ticker Slug: Ticker: MRK Exchange: NYSE read more